Zobeida Cruz-Monserrate1, Kristyn Gumpper2, Valentina Pita2, Phil A Hart3, Christopher Forsmark4, David C Whitcomb5, Dhiraj Yadav5, Richard T Waldron6, Stephen Pandol6, Hanno Steen7, Vincent Anani8, Natasha Kanwar8, Santhi Swaroop Vege8, Savi Appana9, Liang Li9, Jose Serrano10, Jo Ann S Rinaudo11, Mark Topazian8, Darwin L Conwell3. 1. Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA; The James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: zobeida.cruz-monserrate@osumc.edu. 2. Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA; The James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 3. Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 4. University of Florida, Gainesville, FL, USA. 5. University of Pittsburgh, Pittsburgh, PA, USA. 6. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 7. Department of Pathology, Boston Children's Hospital, Boston, MA, USA; Departments of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. 8. The Mayo Clinic, Rochester, MN, USA. 9. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10. Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA. 11. Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.
Abstract
BACKGROUND: Chronic pancreatitis (CP) does not have diagnostic or prognostic biomarkers. CP is the end stage of a progressive inflammatory syndrome that is diagnosed at late stages by morphologic features. To diagnose earlier stages of the disease, a new mechanistic definition was established based on identifying underlying pathogenic processes and biomarker evidence of disease activity and stage. Although multiple risk factors are known, the corresponding biomarkers needed to make a highly accurate diagnosis of earlier disease stages have not been established. The goal of this study is to systematically analyze the literature to identify the most likely candidates for development into biomarkers of CP. METHODS: We conducted a systematic review of candidate analytes from easily accessible biological fluids and identified 67 studies that compared CP to nonpancreatic-disease controls. We then ranked candidate biomarkers for sensitivity and specificity by area under the receiver operator curves (AUROCs). RESULTS: Five biomarkers had a large effect size (an AUROC > 0.96), whereas 30 biomarkers had a moderate effect size (an AUROC between 0.96 and 0.83) for distinguishing CP cases from controls or other diseases. However, the studies reviewed had marked variability in design, enrollment criteria, and biospecimen sample handling and collection. CONCLUSIONS: Several biomarkers have the potential for evaluation in prospective cohort studies and should be correlated with risk factors, clinical features, imaging studies and outcomes. The Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreas Cancer provides recommendations for avoiding design biases and heterogeneity in sample collection and handling in future studies.
BACKGROUND: Chronic pancreatitis (CP) does not have diagnostic or prognostic biomarkers. CP is the end stage of a progressive inflammatory syndrome that is diagnosed at late stages by morphologic features. To diagnose earlier stages of the disease, a new mechanistic definition was established based on identifying underlying pathogenic processes and biomarker evidence of disease activity and stage. Although multiple risk factors are known, the corresponding biomarkers needed to make a highly accurate diagnosis of earlier disease stages have not been established. The goal of this study is to systematically analyze the literature to identify the most likely candidates for development into biomarkers of CP. METHODS: We conducted a systematic review of candidate analytes from easily accessible biological fluids and identified 67 studies that compared CP to nonpancreatic-disease controls. We then ranked candidate biomarkers for sensitivity and specificity by area under the receiver operator curves (AUROCs). RESULTS: Five biomarkers had a large effect size (an AUROC > 0.96), whereas 30 biomarkers had a moderate effect size (an AUROC between 0.96 and 0.83) for distinguishing CP cases from controls or other diseases. However, the studies reviewed had marked variability in design, enrollment criteria, and biospecimen sample handling and collection. CONCLUSIONS: Several biomarkers have the potential for evaluation in prospective cohort studies and should be correlated with risk factors, clinical features, imaging studies and outcomes. The Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreas Cancer provides recommendations for avoiding design biases and heterogeneity in sample collection and handling in future studies.
Authors: K Sri Manjari; D Krishnaveni; A Vidyasagar; B Prabhakar; A Jyothy; Pratibha Nallari; A Venkateshwari Journal: Indian J Gastroenterol Date: 2011-09-24
Authors: Marta Bombardo; Rong Chen; Ermanno Malagola; Enrica Saponara; Andrew P Hills; Rolf Graf; Sabrina Sonda Journal: Mol Pharmacol Date: 2018-06-07 Impact factor: 4.436
Authors: Joao A Paulo; Vivek Kadiyala; Linda S Lee; Peter A Banks; Darwin L Conwell; Hanno Steen Journal: J Proteome Res Date: 2012-02-07 Impact factor: 4.466
Authors: Dhiraj Yadav; Walter G Park; Evan L Fogel; Liang Li; Suresh T Chari; Ziding Feng; William E Fisher; Christopher E Forsmark; Christie Y Jeon; Aida Habtezion; Phil A Hart; Steven J Hughes; Mohamed O Othman; Jo Ann S Rinaudo; Stephen J Pandol; Temel Tirkes; Jose Serrano; Sudhir Srivastava; Stephen K Van Den Eeden; David C Whitcomb; Mark Topazian; Darwin L Conwell Journal: Pancreas Date: 2018 Nov/Dec Impact factor: 3.327
Authors: Erika Y Faraoni; Cynthia Ju; Simon C Robson; Holger K Eltzschig; Jennifer M Bailey-Lundberg Journal: Front Physiol Date: 2022-03-14 Impact factor: 4.755